SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it’s a Great Place To Work – 27 percentage points higher than the average U.S. company. “It’s rare to work somewhere where everyone ...

Core Points - Myriad Genetics, Inc. has received the Great Place To Work Certification for the second consecutive year, with 84% of employees affirming it as a great workplace, which is 27 percentage points higher than the average U.S. company [1][2][3] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic tests that assess disease risk and guide treatment decisions [4] Employee Experience - Employees report a positive work environment, highlighting inclusivity, work/life balance, and a culture that values their opinions and preferences [2][3] - The Great Place To Work Certification reflects Myriad's commitment to fostering an open and collaborative work environment [3] Recognition and Impact - The Great Place To Work Certification is a significant achievement that indicates Myriad Genetics is among the top companies for employee experience, recognized globally for its high-trust workplace [5][6]

Core Insights - A nationwide survey indicates that 40% of Americans feel 'depressed and/or anxious' during the election season, highlighting the impact of politics on mental health [1][2] - The survey reveals that 38% of Americans report increased anxiety due to news and social media related to the election, while 35% feel overwhelmed by the amount of information [1][2] - Only 37% of Americans diagnosed with depression and/or anxiety are currently receiving mental health treatment, indicating a significant gap in care [2] Company Insights - Myriad Genetics, Inc. offers the GeneSight test, which provides clinicians with genetic information to help tailor medication for mental health conditions [5][6] - The GeneSight Psychotropic test is recognized as a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health issues [5] - The GeneSight Mental Health Monitor is part of a series aimed at tracking the mental health effects of the election season, with further surveys planned for September and October [2][3] Industry Insights - The survey was conducted by ACUPOLL Precision Research, involving a representative sample of 1,000 U.S. adults, with a margin of error of +/- 3% [3] - The ongoing mental health crisis in the United States is underscored by the survey results, emphasizing the need for effective treatment methods combining medication and therapy [2] - The GeneSight test is positioned as a valuable tool for clinicians, especially during the heightened anxiety associated with the election period [8]

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Survey show that politics and elections tend to trouble our nation’s mental wellbeing,” said Thomas J. Valente, a psychiatrist f ...

Myriad Genetics, Inc. (MYGN) recently announced a collaboration with GSK plc (GSK) to advance in the field of genetic testing. The latest development is intended to improve access to homologous recombination deficiency (HRD) diagnostic testing for high-grade ovarian cancer (HGSOC) patients.With this alliance, Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests, collectively known as Myriad's MyChoice Tests, are now part of a new sponsored testing program that is accessible in Argentina, Brazil, Chile, Co ...

Myriad Genetics’ (MYGN) strong product portfolio raises our optimism. The company’s impressive growth strategy also encourages us. However, macroeconomic issues impede growth. The stock carries a Zacks Rank #3 (Hold) currently.Myriad Genetics has so far made significant progress with its three strategic imperatives. First, the company is developing best-in-class quality products, services and accessibility to accelerate growth and reach more patients across diverse backgrounds. Second, the company is buildi ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad's MyChoice Tests) is now available in Argentina, Braz ...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad's breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick mode ...

Core Insights - Myriad Genetics announced the validation of its RiskScore tool for breast cancer risk assessment, published in Genetics in Medicine, which combines a polygenic risk score with the Tyrer-Cuzick model [1][2] Study Overview - The study analyzed outcomes from over 130,000 women who underwent Myriad's MyRisk Hereditary Cancer Test with RiskScore, showing that RiskScore significantly improved predictive accuracy for breast cancer risk compared to the Tyrer-Cuzick model alone, with an approximate two-fold increase in accuracy [2][3] - The study included women tested between 2017-2019 who did not have known pathogenic variants associated with breast cancer and had no prior breast cancer diagnosis [5] Clinical Implications - RiskScore reclassified approximately 1 in 5 women compared to the Tyrer-Cuzick model, potentially leading to better identification of women who may benefit from enhanced surveillance measures [3][4] - The integration of a polygenic risk score for all ancestries into Myriad's precision medicine tool allows for a more comprehensive risk assessment, particularly for women without pathogenic germline mutations [4][5] Company Background - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [6]